Replies to post #28114 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

I haven't tallied it, but the majority of CNS partnership deals do not include equity stakes. So he does not have to do 'one or the other',and certainly not before the SA results are out. If SA data is clean and positive, he will be counting on either a cash-up-front partnering deal, or a buyout. If not, if the data is negative, he bought a couple more months with the last financing, and that would be used for a 'put your best offer on the table' finale.

I suppose if the SA data is good, and if Cortex gets enough cash and cred to raise the stock price, a case can be made for a reverse-split, preceding another financing at a higher pps. But I am more concerned about the first two 'If' events than what would happen afterward.

NeuroInvestment

[ombowstring]

gfp, I don't mean to question you, but are you absolutely sure that if Cortex did a reverse split, they would suddenly have an abundance of new shares to work with?

If they did a 10-1 reverse split, the 103 million fully diluted shares (as you calculated it), would then be reduced to 10.3 million. And with 105 million authorized, they would then have @ 95 million shares to play with, make a deal with, or even do another financing?